Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6853
Peer-review started: June 19, 2020
First decision: September 12, 2020
Revised: September 29, 2020
Accepted: October 19, 2020
Article in press: October 19, 2020
Published online: November 21, 2020
Processing time: 153 Days and 14.2 Hours
Cancer stem cells (CSCs) are a subpopulation of cancer cells with the potential of self-renewal and differentiation. CSCs play critical roles in tumorigenesis, recurrence, metastasis, radiation tolerance and chemoresistance.
To assess the expression patterns and clinical potential of doublecortin-like kinase 1 (DCLK1) and leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5), as prognostic CSC markers of colorectal cancer (CRC).
The expression of DCLK1 and Lgr5 in CRC tissue sections from 92 patients was determined by immunohistochemistry. Each case was evaluated using a combined scoring method based on signal intensity staining (scored 0-3) and the proportion of positively stained cancer cells (scored 0-3). The final staining score was calculated as the intensity score multiplied by the proportion score. Low expression of DCLK1 and Lgr5 was defined as a score of 0-3; high expression of DCLK1 and Lgr5 was defined as a score of ≥ 4. Specimens were categorized as either high or low expression, and the correlation between the expression of DCLK1 or Lgr5 and clinicopathological factors was investigated.
DCLK1 and Lgr5 expression levels were significantly positively correlated. CRC patients with high DCLK1, Lgr5 and DCLK1/Lgr5 expressions had poorer progression-free survival and overall survival. Moreover, high expression of DCLK1 was an independent prognostic factor for recurrence and overall survival in patients with CRC by multivariate analysis (P = 0.026 and P = 0.049, respectively).
DCLK1 may be a potential CSC marker for the recurrence and survival of CRC patients.
Core Tip: The role of doublecortin-like kinase 1 (DCLK1) and leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) in patients with stage II/III colorectal cancer (CRC) remains uncertain. In this study, we found a positive correlation between the expression of DCLK1 and Lgr5, suggesting that DCLK1 and Lgr5 were involved in the malignant pathological development of CRC. High DCLK1 expression could predict the risk of recurrence and survival in CRC patients after surgery, which may be used as a potential cancer stem cells marker for the recurrence and survival of stage II/III CRC patients.